Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
AGTC logo — Visionary science for life-changing cures.

AGTC

Visionary science for life-changing cures.

Founded 1999 United States Alachua, United States 117 employees Post-IPO Equity Total: $195.05M Biotechnology, Health Care +1

General Information

Company Name AGTC
Founded Year 1999
Location United States Alachua, United States
Employees 117
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with AGTC. To contact AGTC, visit agtc.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does AGTC compare?

A PDF of AGTC and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting AGTC soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About AGTC

AGTC is a clinical-stage biotechnology company dedicated to revolutionizing patient lives through its groundbreaking gene therapy platform. Specializing in ophthalmology, the company is focused on addressing inherited orphan diseases of the eye caused by mutations in single genes that significantly impair visual function and presently lack effective treatments. AGTC's product pipeline encompasses six ophthalmology development programs across five targets, including X-linked retinoschisis, X-linked retinitis pigmentosa, achromatopsia, wet age-related macular degeneration, and blue cone monochromacy, along with two non-ophthalmology programs.

AGTC is also actively exploring genetic defects leading to deafness and anticipates advancing several product candidates into development in the coming years. Founded in 1999, AGTC employs a highly targeted approach in selecting and designing its product candidates, focusing on indications with high unmet medical needs, clinical feasibility, and commercial potential. The company boasts a remarkable intellectual property portfolio and extensive expertise in gene therapy product design and manufacturing.

Recently, AGTC secured a $10.00M Post-IPO Equity investment on 12 July 2022. The company, headquartered in the United States, continues to attract interest and support for its visionary science in life-changing cures.

Business keywords: gene therapy, ophthalmology, clinical-stage, genetic diseases, rare diseases, innovation, intellectual property, clinical trials, treatment development, commercial potential, scientific advancement, precision medicine

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $10.00M -
12 Jul 2022
Post IPO Equity $74.50M -
28 Jan 2021
Post IPO Equity $32.50M -
06 Feb 2020
Series B $37.50M 6
Intersouth Partners InterWest Partners Alta Partners
Intersouth Partners, InterWest Partners +4
19 Nov 2012
Debt Financing $750.00K -
03 May 2012
Grant $1.00M -
14 Sep 2010
Venture Round $11.80M 3
Intersouth Partners InterWest Partners MedImmune Ventures
Intersouth Partners, InterWest Partners +1
09 Jun 2009
Venture Round $27.00M 1
Intersouth Partners
Intersouth Partners
01 Nov 2003

AGTC Alternatives & Competitors

View All Alternatives
AGTC vs
GenSight Biologics
GenSight Biologics France

Applying pathbreaking science to transform the lives of patients with severe retinal neurodegenerati...

Post-IPO Equity
34 employees
Biotechnology, Health Care
Compare AGTC vs GenSight Biologics
AGTC vs
Atsena Therapeutics
Atsena Therapeutics

Clinical-stage gene therapy company developing treatments to reverse/prevent blindness from inherite...

Series C
46 employees
Biotechnology, Health Care
AGTC vs
Benitec Biopharma Inc.
Benitec Biopharma Inc. United States

Silencing genes for life

Post-IPO Equity
16 employees
Biotechnology, Health Care
Compare AGTC vs Benitec Biopharma Inc.
View all alternatives

FAQ About AGTC

Visionary science for life-changing cures.
AGTC was founded in 1999.
AGTC is headquartered in Alachua, United States.
AGTC operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on gene therapy, ophthalmology, clinical-stage and genetic diseases.
AGTC has approximately 117 employees.
AGTC has completed 8 funding rounds, raising a total of $195.05M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to AGTC include GenSight Biologics, Atsena Therapeutics, Benitec Biopharma Inc., Homology Medicines, Genprex, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
AGTC and GenSight Biologics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for AGTC, https://bouncewatch.com/company/agtc, updated 29 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes